Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the importance of long-term monitoring. A recent study reveals CAR T-cell therapy ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

A novel in vivo CD19 CAR-T therapy achieved complete remission in a DLBCL patient without lymphodepletion, showing sustained efficacy over three months. The therapy demonstrated safety, with no ...

Efforts to develop off-the-shelf (OTS) cell therapies are accelerating across global biotech, as researchers aim to make next-generation cancer treatments more accessible, affordable, and consistent.

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...